Cancer Treatment News and Research

RSS

AVEO presents tivozanib Phase 2 study results at ESMO Congress

AVEO Pharmaceuticals, Inc. a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) were presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.

11 Oct 2010

New natural dietary components inhibit breast cancer cells

Researchers at Indiana University and Methodist Research Institute have published the dramatic effects of a natural formula against breast cancer. The impressive results are found in the most recent publication of Integrative Cancer Therapies. Lead investigator Dr. Daniel Sliva says, The formula we studied inhibits growth of highly metastatic human breast cancer cells, and suppresses metastatic potential of these cells.

11 Oct 2010

Phase-II clinical trial of MLN8237 drug shows promising results for treating ovarian cancer

A drug being developed as a treatment for ovarian cancer has shown single agent activity with durable disease control in some patients in a Phase-II clinical trial, an international research group has reported.

11 Oct 2010

Anti-HER2 antibody-drug conjugate effective as first-line therapy for advanced breast cancer: Research

A new type of breast cancer treatment has shown encouraging activity as a first-line therapy in HER2-positive metastatic disease, researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

11 Oct 2010

AMIC signs world-wide license for brachytherapy seed with fast-dissolving matrix

Advanced Medical Isotope Corporation, a company engaged in the production and distribution of medical isotopes, is delighted to announce the execution of an exclusive world-wide license for patented technology for a proprietary brachytherapy seed with a fast-dissolving matrix for optimized delivery of radionuclides to cancer tissue.

7 Oct 2010

Study shows radioembolisation with TheraSphere effective for primary liver cancer

MDS Nordion, a leading provider of products and services to the global health science market, today announced that the first large European study using Yttrium-90 (Y-90) glass microspheres has been published on the use of TheraSphere, an innovative radioembolisation therapy for the localised treatment of patients with advanced hepatocellular carcinoma (HCC) or primary liver cancer.

7 Oct 2010

Should Medicare consider cost-effectiveness when setting reimbursement rates?

Medicare reimbursement rates should be based on how cost effective the treatment is for a particular illness, according to a piece by two policy experts in the October edition of Health Affairs.

7 Oct 2010

Majority of cancer patients are concerned about treatment costs: MDLinx

Ninety five percent of the nation's oncologists report a rise in their patients' concerns over treatment costs in the past six months, according to a survey conducted by MDLinx, one of the U.S.'s largest doctor portals.

7 Oct 2010

Caris Target Now molecular tumor profiling increases PFS in cancer patients

Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic services, today announced highlights from a multi-center, prospective, pilot study published in the Journal of Clinical Oncology.

7 Oct 2010

American Cancer Society awards 94 national research, training grants to 70 institutions nationwide

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 94 national research and training grants totaling $46,633,000 to 70 institutions nationwide in the first of two grants cycles for 2011.

7 Oct 2010

Lixte, NCI collaborate for clinical evaluation of LB-100 compound

Lixte Biotechnology Holdings announced today that the National Cancer Institute Experimental Therapeutics (NExT) Program Senior Advisory Committee (SAC), Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI), National Institutes of Health (NIH), signed a NExT Material Transfer Agreement formalizing a collaboration with Lixte Biotechnology Holdings, Inc. for clinical evaluation of LB-100, one of Lixte's lead anti-cancer compounds.

6 Oct 2010

Amgen announces PRIME '203' and '181' Phase 3 trial results

Amgen today announced that results from the PRIME '203' and '181' pivotal Phase 3 trials evaluating Vectibix (panitumumab) in combination with chemotherapy (FOLFOX or FOLFIRI) as a first and second-line treatment for metastatic colorectal cancer (mCRC), respectively, were published online in the Journal of Clinical Oncology.

5 Oct 2010

AmeriCares, AstraZeneca enter commitment to expand breast cancer treatment in Cambodia

AmeriCares and AstraZeneca Pharmaceuticals have made a three-year commitment to expand early breast cancer detection and treatment in Cambodia in hopes of increasing survival rates.

5 Oct 2010

Mind-body intervention effective in treating persistent fatigue in breast cancer survivors

A group-based, holistic, mind-body intervention was equally effective in treating persistent fatigue and improving quality of life for breast cancer survivors, regardless of their race.

4 Oct 2010

Cancer patients likely to experience memory impairment: Study

People with a history of cancer have a 40 percent greater likelihood of experiencing memory problems that interfere with daily functioning, compared with those who have not had cancer, according to results of a new, large study.

4 Oct 2010

Breast cancer breakthrough

New research on gene expression provides a breakthrough in breast cancer treatment. Women who have triple-negative breast cancer are a small proportion of breast cancer cases, but it is difficult to treat and might have a more aggressive clinical course than other forms of the disease.

30 Sep 2010

New form of immunotherapy increases survival in children with neuroblastoma

Administering a new form of immunotherapy to children with neuroblastoma, a nervous system cancer, increased the percentage of those who were alive and free of disease progression after two years, according to researchers at the University of California, San Diego School of Medicine and fellow institutions. The percentage rose from 46 percent for children receiving a standard therapy to 66 percent for children receiving immunotherapy plus standard therapy, according to the study published in the Sept. 30, 2010 issue of the New England Journal of Medicine.

30 Sep 2010

New immunotherapy regimen improves survival rate in children with neuroblastoma: Research

30 Sep 2010

New program offers options for fertility preservation in children with cancer

It is estimated that 1 in 500 children will be diagnosed with a form of childhood cancer. Fortunately, with the use of aggressive treatment modalities, more than 75% of these children will be cured. Therefore, many of these children and parents are looking beyond the cancer at important quality of life issues and guiding their treatments to assure "normal" post-cancer survivorship.

29 Sep 2010

AACR to host Third Conference on The Science of Cancer Health Disparities

The American Association for Cancer Research will host its Third Conference on The Science of Cancer Health Disparities at the Loews Hotel in Miami from Sept. 30 to Oct. 3, 2010.

29 Sep 2010

Cancer Treatment News and Research

AVEO presents tivozanib Phase 2 study results at ESMO Congress

New natural dietary components inhibit breast cancer cells

Phase-II clinical trial of MLN8237 drug shows promising results for treating ovarian cancer

Anti-HER2 antibody-drug conjugate effective as first-line therapy for advanced breast cancer: Research

AMIC signs world-wide license for brachytherapy seed with fast-dissolving matrix

Study shows radioembolisation with TheraSphere effective for primary liver cancer

Should Medicare consider cost-effectiveness when setting reimbursement rates?

Majority of cancer patients are concerned about treatment costs: MDLinx

Caris Target Now molecular tumor profiling increases PFS in cancer patients

American Cancer Society awards 94 national research, training grants to 70 institutions nationwide

Lixte, NCI collaborate for clinical evaluation of LB-100 compound

Amgen announces PRIME '203' and '181' Phase 3 trial results

AmeriCares, AstraZeneca enter commitment to expand breast cancer treatment in Cambodia

Mind-body intervention effective in treating persistent fatigue in breast cancer survivors

Cancer patients likely to experience memory impairment: Study

Breast cancer breakthrough

New form of immunotherapy increases survival in children with neuroblastoma

New immunotherapy regimen improves survival rate in children with neuroblastoma: Research

New program offers options for fertility preservation in children with cancer

AACR to host Third Conference on The Science of Cancer Health Disparities

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News